S&P 500   3,111.70 (-0.03%)
DOW   27,623.32 (-0.10%)
QQQ   202.37 (-0.03%)
AAPL   264.26 (+0.96%)
FB   198.82 (+0.06%)
MSFT   149.89 (+0.03%)
GOOGL   1,318.17 (-0.06%)
AMZN   1,746.86 (-0.79%)
CGC   18.75 (+2.01%)
NVDA   208.52 (-0.43%)
MU   46.42 (+0.26%)
BABA   199.07 (+2.75%)
GE   10.84 (-0.55%)
T   38.29 (+0.50%)
AMD   39.96 (+0.68%)
ACB   2.48 (+0.00%)
NFLX   300.94 (-1.11%)
BAC   33.07 (-0.24%)
GILD   65.96 (-1.18%)
DIS   147.88 (-0.27%)
S&P 500   3,111.70 (-0.03%)
DOW   27,623.32 (-0.10%)
QQQ   202.37 (-0.03%)
AAPL   264.26 (+0.96%)
FB   198.82 (+0.06%)
MSFT   149.89 (+0.03%)
GOOGL   1,318.17 (-0.06%)
AMZN   1,746.86 (-0.79%)
CGC   18.75 (+2.01%)
NVDA   208.52 (-0.43%)
MU   46.42 (+0.26%)
BABA   199.07 (+2.75%)
GE   10.84 (-0.55%)
T   38.29 (+0.50%)
AMD   39.96 (+0.68%)
ACB   2.48 (+0.00%)
NFLX   300.94 (-1.11%)
BAC   33.07 (-0.24%)
GILD   65.96 (-1.18%)
DIS   147.88 (-0.27%)
S&P 500   3,111.70 (-0.03%)
DOW   27,623.32 (-0.10%)
QQQ   202.37 (-0.03%)
AAPL   264.26 (+0.96%)
FB   198.82 (+0.06%)
MSFT   149.89 (+0.03%)
GOOGL   1,318.17 (-0.06%)
AMZN   1,746.86 (-0.79%)
CGC   18.75 (+2.01%)
NVDA   208.52 (-0.43%)
MU   46.42 (+0.26%)
BABA   199.07 (+2.75%)
GE   10.84 (-0.55%)
T   38.29 (+0.50%)
AMD   39.96 (+0.68%)
ACB   2.48 (+0.00%)
NFLX   300.94 (-1.11%)
BAC   33.07 (-0.24%)
GILD   65.96 (-1.18%)
DIS   147.88 (-0.27%)
S&P 500   3,111.70 (-0.03%)
DOW   27,623.32 (-0.10%)
QQQ   202.37 (-0.03%)
AAPL   264.26 (+0.96%)
FB   198.82 (+0.06%)
MSFT   149.89 (+0.03%)
GOOGL   1,318.17 (-0.06%)
AMZN   1,746.86 (-0.79%)
CGC   18.75 (+2.01%)
NVDA   208.52 (-0.43%)
MU   46.42 (+0.26%)
BABA   199.07 (+2.75%)
GE   10.84 (-0.55%)
T   38.29 (+0.50%)
AMD   39.96 (+0.68%)
ACB   2.48 (+0.00%)
NFLX   300.94 (-1.11%)
BAC   33.07 (-0.24%)
GILD   65.96 (-1.18%)
DIS   147.88 (-0.27%)
Log in

NYSEAMERICAN:ATNM - Actinium Pharmaceuticals Stock Price, Forecast & News

$0.24
-0.01 (-4.00 %)
(As of 12/5/2019 12:16 PM ET)
Today's Range
$0.24
Now: $0.24
$0.26
50-Day Range N/A
52-Week Range
$0.19
Now: $0.24
$0.71
Volume76,065 shs
Average Volume1.30 million shs
Market Capitalization$39.53 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Actinium Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, Iomab-B that is in a pivotal Phase III clinical trial as an induction and conditioning agent in patients over the age of 55 with relapsed or refractory acute myeloid leukemia prior to receiving a bone marrow transplant, also known as a hematopoietic stem cell transplant. Read More…

Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolNYSEAMERICAN:ATNM
CUSIPN/A
CIKN/A
Phone+1-646-6773875

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees30
Market Cap$39.53 million
Next Earnings Date3/17/2020 (Estimated)
OptionableOptionable

Receive ATNM News and Ratings via Email

Sign-up to receive the latest news and ratings for ATNM and its competitors with MarketBeat's FREE daily newsletter.


Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) Frequently Asked Questions

What is Actinium Pharmaceuticals' stock symbol?

Actinium Pharmaceuticals trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "ATNM."

How were Actinium Pharmaceuticals' earnings last quarter?

Actinium Pharmaceuticals Inc (NYSEAMERICAN:ATNM) issued its quarterly earnings data on Tuesday, November, 12th. The biotechnology company reported ($0.04) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.04) by $0.00. View Actinium Pharmaceuticals' Earnings History.

When is Actinium Pharmaceuticals' next earnings date?

Actinium Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, March 17th 2020. View Earnings Estimates for Actinium Pharmaceuticals.

What price target have analysts set for ATNM?

3 analysts have issued 1-year price objectives for Actinium Pharmaceuticals' stock. Their forecasts range from $1.50 to $5.00. On average, they anticipate Actinium Pharmaceuticals' share price to reach $3.25 in the next twelve months. This suggests a possible upside of 1,254.2% from the stock's current price. View Analyst Price Targets for Actinium Pharmaceuticals.

What is the consensus analysts' recommendation for Actinium Pharmaceuticals?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Actinium Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Actinium Pharmaceuticals.

What are Wall Street analysts saying about Actinium Pharmaceuticals stock?

Here are some recent quotes from research analysts about Actinium Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Actinium Pharmaceuticals, Inc. is a biopharmaceutical company. It specializes in the development of cancer drugs. The company's principal product candidates under different developmental stages include Actimab-A for the treatment of acute myeloid leukemia in elderly patients and Iomab-B used to condition the bone marrow of patients. Actinium Pharmaceuticals, Inc. is based in New York. " (11/20/2019)
  • 2. Maxim Group analysts commented, "Actinium reported 4Q18 and FY18 with a net loss of ($6.4M) and ($23.7M), respectively. The company ended the year with $13.6M in cash on the balance sheet (not including $2.5M warrant exercises). The company also has a $30M ATM in place. Combined, the company should have sufficient runway to get the P3 data for Iomab in 1H20." (3/20/2019)

Has Actinium Pharmaceuticals been receiving favorable news coverage?

Media coverage about ATNM stock has trended somewhat positive this week, according to InfoTrie Sentiment. The research group identifies negative and positive media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Actinium Pharmaceuticals earned a news impact score of 0.9 on InfoTrie's scale. They also assigned news articles about the biotechnology company a news buzz of 1.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for Actinium Pharmaceuticals.

Are investors shorting Actinium Pharmaceuticals?

Actinium Pharmaceuticals saw a increase in short interest in the month of November. As of November 15th, there was short interest totalling 3,810,000 shares, an increase of 32.8% from the October 31st total of 2,870,000 shares. Based on an average daily volume of 1,470,000 shares, the short-interest ratio is presently 2.6 days. Currently, 2.5% of the company's stock are sold short. View Actinium Pharmaceuticals' Current Options Chain.

Who are some of Actinium Pharmaceuticals' key competitors?

What other stocks do shareholders of Actinium Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Actinium Pharmaceuticals investors own include OHR Pharmaceutical (OHRP), Fitbit (FIT), Global Ship Lease (GSL), Opko Health (OPK), TransEnterix (TRXC), Tandem Diabetes Care (TNDM), Cancer Genetics (CGIX), Sorrento Therapeutics (SRNE), AK Steel (AKS) and Align Technology (ALGN).

Who are Actinium Pharmaceuticals' key executives?

Actinium Pharmaceuticals' management team includes the folowing people:
  • Mr. Sandesh C. Seth, Chairman & CEO (Age 55)
  • Mr. Steven O'Loughlin BS, Principal Financial & Accounting Officer (Age 33)
  • Dr. Dale L. Ludwig Ph.D., Chief Scientific Officer (Age 57)
  • Dr. Mark S. Berger, Chief Medical Officer (Age 64)
  • Mr. Anil Kapur, Chief Commercial Officer (Age 50)

Who are Actinium Pharmaceuticals' major shareholders?

Actinium Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Sabby Management LLC (5.34%) and Endurant Capital Management LP (0.82%). Company insiders that own Actinium Pharmaceuticals stock include Ajit Shetty, Dale L Ludwig, Sandesh Seth and Steve O'loughlin. View Institutional Ownership Trends for Actinium Pharmaceuticals.

Which institutional investors are selling Actinium Pharmaceuticals stock?

ATNM stock was sold by a variety of institutional investors in the last quarter, including Endurant Capital Management LP. View Insider Buying and Selling for Actinium Pharmaceuticals.

Which institutional investors are buying Actinium Pharmaceuticals stock?

ATNM stock was acquired by a variety of institutional investors in the last quarter, including Sabby Management LLC. Company insiders that have bought Actinium Pharmaceuticals stock in the last two years include Ajit Shetty, Dale L Ludwig, Sandesh Seth and Steve O'loughlin. View Insider Buying and Selling for Actinium Pharmaceuticals.

How do I buy shares of Actinium Pharmaceuticals?

Shares of ATNM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Actinium Pharmaceuticals' stock price today?

One share of ATNM stock can currently be purchased for approximately $0.24.

How big of a company is Actinium Pharmaceuticals?

Actinium Pharmaceuticals has a market capitalization of $39.53 million. Actinium Pharmaceuticals employs 30 workers across the globe.View Additional Information About Actinium Pharmaceuticals.

What is Actinium Pharmaceuticals' official website?

The official website for Actinium Pharmaceuticals is http://www.actiniumpharmaceuticals.com/.

How can I contact Actinium Pharmaceuticals?

Actinium Pharmaceuticals' mailing address is 275 Madison Avenue, 7Th Floor, NEW YORK, NY 10016, United States. The biotechnology company can be reached via phone at +1-646-6773875.


MarketBeat Community Rating for Actinium Pharmaceuticals (NYSEAMERICAN ATNM)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  278 (Vote Outperform)
Underperform Votes:  150 (Vote Underperform)
Total Votes:  428
MarketBeat's community ratings are surveys of what our community members think about Actinium Pharmaceuticals and other stocks. Vote "Outperform" if you believe ATNM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ATNM will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/5/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel